Drug intelligence / Profile preview

avt10

Development stage: Preclinical
Lead developer: Alvotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AVT10 is a biosimilar candidate developed by Alvotech to reference Cimzia (certolizumab pegol), a monoclonal antibody targeting tumor necrosis factor alpha (TNF-α) for the treatment of chronic inflammatory and rheumatic diseases. Certolizumab pegol works by binding specifically to TNF-α and inhibiting its activity, thereby reducing inflammation and disease symptoms in conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease. AVT10 is currently the only global biosimilar targeting Cimzia under development, aiming to improve access to high-quality biologics across Europe[7].

Brand names: AVT10AVT-10AVT 10
Other names: AVT10AVT-10AVT 10

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on avt10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avt10.

Explore the full profile